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Cationic antimicrobial peptides and polymyxins are a group of naturally occurring antibiotics
that can also possess immunomodulatory activities. They are considered a new source
of antibiotics for treating infections by bacteria that are resistant to conventional antibi-
otics. Members of the genus Burkholderia, which includes various human pathogens, are
inherently resistant to antimicrobial peptides. The resistance is several orders of magni-
tude higher than that of other Gram-negative bacteria such as Escherichia coli, Salmonella
enterica, or Pseudomonas aeruginosa. This review summarizes our current understanding
of antimicrobial peptide and polymyxin B resistance in the genusBurkholderia.These bacte-
ria possess major and minor resistance mechanisms that will be described in detail. Recent
studies have revealed that many other emerging Gram-negative opportunistic pathogens
may also be inherently resistant to antimicrobial peptides and polymyxins and we propose
that Burkholderia sp. are a model system to investigate the molecular basis of the resis-
tance in extremely resistant bacteria. Understanding resistance in these types of bacteria
will be important if antimicrobial peptides come to be used regularly for the treatment of
infections by susceptible bacteria because this may lead to increased resistance in the
species that are currently susceptible and may also open up new niches for opportunistic
pathogens with high inherent resistance.
Keywords: Burkholderia, antimicrobial peptides, polymyxin, outer membrane, lipopolysaccharide, antibiotics,
bacterial resistance mechanisms
INTRODUCTION
As the resistance of pathogenic bacteria to conventional antibi-
otics is on the rise, new sources of antibiotics are being sought
including cationic antimicrobial peptides and polymyxins (Han-
cock and Sahl, 2006). These compounds are naturally occurring
and are produced bymost forms of life frommicrobes tomammals
(Yeaman andYount, 2007). They can act as antibiotics against bac-
teria but also have a wide range of important immunomodulatory
activities in vivo (Lai and Gallo, 2009). Antimicrobial peptides
represent a potential new source of antibiotics for treatment of
various bacterial infections, including opportunistic infections in
cystic ﬁbrosis (CF) patients (Zhang et al., 2005), and are being
used to as a last resort to treat some infections by multidrug
resistant bacteria (Zavascki et al., 2007). Antimicrobial peptides
cause disruption of the cytoplasmic membrane of bacteria (inner
membrane in Gram-negative bacteria), but can also inhibit intra-
cellular processes such as nucleic acid, DNA, or protein synthesis
(Brogden, 2005). Resistance mechanisms have been characterized
in various Gram-negative bacteria, including Escherichia coli, Sal-
monella enterica, and Pseudomonas aeruginosa. Many resistance
mechanisms in Gram-negative bacteria involve alterations of the
lipopolysaccharide (LPS) molecule of the outer membrane, which
reduce the access of antimicrobial peptides and polymyxins to the
inner membrane (Vaara et al., 1981; Gunn et al., 1998; Guo et al.,
1998; Tamayo et al., 2005). Many Gram-positive bacteria display
analogous alterations to their lipoteichoic and wall teichoic acids
resulting in reduced access of these compounds to their cytoplas-
mic membranes (Peschel et al., 1999; Kovács et al., 2006; Giaouris
et al., 2008).
A group of extremely antimicrobial peptide resistant Gram-
negative bacteria exist and the best characterized of these organ-
isms are species of the genusBurkholderia. This review summarizes
the current state of knowledge concerning antimicrobial peptide
and polymyxin resistance among the Burkholderia and discusses
how the treatment of infections caused by sensitive bacteria with
antimicrobial peptides or polymyxins could impact infections by
resistant Gram-negative bacteria.
THE GENUS BURKHOLDERIA: PATHOGENS AMONGST THE
WEEDS
The genus Burkholderia comprises over 40 species of bacteria,
most of which have been isolated from soil or fresh water. Mem-
bers of this genus are symbionts of plants, fungi, and insects
and pathogens of plants, fungi, and non-human mammals (for
an excellent review on the distribution of Burkholderia bacteria
within the environment see Compant et al., 2008). Within this
genus are a group of at least 17 species, collectively known as the
Burkholderia cepacia complex, that cause chronic opportunistic
infections particularly in patients with CF or chronic granuloma-
tous disease (Mahenthiralingam et al., 2005; Vanlaere et al., 2009).
The genus also includes two species that cause acute infections
in humans: B. pseudomallei, the causative agent of melioidosis
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(Cheng and Currie, 2005), and B. mallei, a facultative intracellu-
lar bacterium that causes glanders (Gregory et al., 2007). Acute
and opportunistic infections by other members of the genus have
also been reported (Gerrits et al., 2005; Sudo et al., 2005; Glass
et al., 2006; Weinberg et al., 2007; Lestin et al., 2008; Deris et al.,
2010).
Within the natural environment abundant opportunities arise
during which Burkholderia bacteria may be exposed to antimi-
crobial peptides, polymyxins, and other similar compounds; this
exposure is likely to have contributed a selective pressure for
the evolution of high levels of resistance in these organisms.
The rhizosphere is home to many microorganisms that produce
antibiotics and many antibiotics have been directly detected from
rhizosphere soil (Berg et al., 2005). These include bacteria such
as Paenibacillus polymyxa, which contains the genetic material
required to make polymyxins, a lantibiotic, bacitracin, and other
antibiotics (Ma et al., 2011). Burkholderia sp. also form symbiotic
and/or pathogenic interactions with insects and plants (Compant
et al., 2008). These hosts also produce antimicrobial peptides
(García-Olmedo et al., 1998; Bulet and Stocklin, 2005) which
Burkholderia bacteria are likely exposed to at some point in their
symbiosis or pathogenesis.
ANTIMICROBIAL PEPTIDE AND POLYMYXIN RESISTANCE IN
THE GENUS BURKHOLDERIA
Members of the genus Burkholderia are inherently resistant to
many antimicrobial agents (Mahenthiralingam et al., 2005); they
have been shown to grow on penicillin as a sole carbon source
(Vermis et al., 2003) and survive in solutions of chlorhexidine
used for disinfection of hospital equipment (Heo et al., 2008). For
the purpose of this review we considered Gram-negative bacteria
to be extremely resistant to antimicrobial peptides and polymyxins
if minimum inhibitory concentration (MIC) values of 500 μg/ml
or more have been reported. Numerous species of Burkholderia
bacteria fall into this category (Table 1). For comparison, reported
MIC values for sensitive Gram-negative bacteria such as E. coli, S.
enterica, and P. aeruginosa are several orders of magnitude lower
than those for Burkholderia sp. (Table 1).
Antimicrobial peptide andpolymyxin resistancehas been inves-
tigated in various different Burkholderia sp. and a variety of
major and minor determinants of antimicrobial peptide and
polymyxin resistance have been proposed for members of the
genus Burkholderia (Figure 1). An early study in B. cepacia (for-
merly Pseudomonas cepacia) showed that unlike P. aeruginosa,
polymyxin B bound poorly to whole cells of B. cepacia and was
unable to permeabilize the outer membrane of B. cepacia to a sec-
ond molecule (1-N -phenylnaphthylamine; Moore and Hancock,
1986); these observations have since been conﬁrmed in B. ceno-
cepacia and B. pseudomallei (Burtnick and Woods, 1999; Ortega
et al., 2009). These initial stages in the action of polymyxin B are
known as the self-promoted uptake pathway, a process by which
a cationic antibiotic displaces divalent cations that bridge LPS
molecules and promote the uptake of other molecules across the
outer membrane by decreasing the permeability of the membrane
(Hancock and Wong, 1984). Moore and Hancock (1986) con-
cluded that unique properties of the B. cepacia outer membrane
Table 1 | Antimicrobial peptide and polymyxin resistance values for many of the studies discussed in the text.
Species/strain Assay Compound Value References
B. pseudomallei 1026b MIC Polymyxin B 128mg/ml Burtnick and Woods (1999)
Colistin 128mg/ml
B. cepacia ATCC 17770 MIC Human β-defensin-3 6.6μg/ml García et al. (2001)
B. vietnamiensis (11/11 strains) MIC Bactenecin 2a >128μg/ml Jassem et al. (2011)
LL-37 >128μg/ml
B. vietnamiensis (10/11 strains) MIC Polymyxin B >75μg/ml
B. vietnamiensis FC0656 MIC Polymyxin B 37.5μg/ml
MIC50 Polymyxin B >1024μg/ml Loutet et al. (2006, 2009)
Melittin >512μg/ml
B. cenocepacia K56-2 Inhibition on solid media Human neutrophil peptide-1 >100μg/ml
B. cenocepacia J2315 MIC50 Polymyxin B >512μg/ml
18 Strains from ﬁve species: MIC50 Polymyxin B >256μg/ml Thwaite et al. (2009)
B. cepacia Calcitermin >256μg/ml
B. multivorans Cecropin A >256μg/ml
B. cenocepacia Granulysin >256μg/ml
B. stabilis LL-37 >256μg/ml
B. vietnamiensis MUC-7 >256μg/ml
P113 >256μg/ml
Ovine polyaspartic acid >256μg/ml
Magainin II 8 to >256μg/ml
S. enterica (Typhimurium) 1408s MIC Polymyxin B 1.9μg/ml Gunn et al. (1998)
P. aeruginosa H103 MIC Polymyxin B 8μg/ml McPhee et al. (2003)
E. coli SC9251 MIC Polymyxin B 0.5μg/ml Vaara and Vaara (1994)
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FIGURE 1 | Proposed antimicrobial peptide and/or polymyxin resistance
mechanisms in Burkholderia species.The model depicts LPS as providing a
major barrier to binding of peptides (Loutet et al., 2011) and the possible role
of the metalloproteases ZmpA and ZmpB in degrading antimicrobial peptides.
The periplasmic protein involved in resistance by an unknown mechanism is
MucD, which is homologous to members of the HtrA protease family. In our
model, IspH, an enzyme involved in the synthesis of isoprenoids could play a
role in antimicrobial peptide resistance by introducing modiﬁcations of the
lipid composition of the inner membrane, while the efﬂux pump NorM could
mediate the efﬂux of peptides that cross the inner membrane and gain
access to the cytoplasm. The regulators RpoE and BCAL2831 participate in
global regulatory responses leading to an increase in antimicrobial peptide
resistance. The genes regulated by RpoE and BCAL2831 and involved in
these responses have not been identiﬁed, but it is likely RpoE regulates
mucD since the genes encoding both proteins are co-transcribed (Flannagan
and Valvano, 2008).
blocked the self-promoted uptake of polymyxin B and that this
explained, at least in part, the high levels of resistance seen in the
organism.
Burtnick and Woods (1999) used a random screen to
identify determinants of antimicrobial peptide resistance in
B. pseudomallei. These authors reported that B. pseudomallei had
the ability to grow in concentrations of polymyxin B as high
at 128mg/ml and obtained polymyxin B-sensitive transposon
mutants in three genes. One gene (waaF) encodes a protein
required for LPS core oligosaccharide biosynthesis. The others
encoded a predicted enzyme with UDP-glucose dehydrogenase
activity and an enzyme called IspH (formerly LytB), which at the
time was thought to be involved in the bacterial stringent response
(Gustafson et al., 1993) but has since been shown to be required
for the synthesis of isoprenoids (Rohdich et al., 2002). All of these
pathways are also involved in antimicrobial peptide andpolymyxin
resistance in B. cenocepacia (Loutet et al., 2006, 2009, 2011; Ortega
et al., 2009).
In numerous Gram-negative bacteria, the sugar 4-amino-4-
deoxy-l-arabinose (Ara4N) is synthesized and then added to the
lipid A component of LPS to increase antimicrobial peptide and
polymyxin resistance (Nummila et al., 1995; Gunn et al., 1998;
Ernst et al., 1999; Winﬁeld et al., 2005). However, in most Gram-
negative bacteria synthesis of this sugar is dispensable under most
growth conditions and the sugar is not normally found in the
lipid A molecule. Many studies have shown that Burkholderia sp.
produce Ara4N constitutively as part of their LPS molecule, in
some cases placing the sugar in both the lipid A and core oligosac-
charide portions of the molecules (Isshiki et al., 1998; Gronow
et al., 2003; Silipo et al., 2005, 2007; Brett et al., 2007; Novem
et al., 2009; Ortega et al., 2009). The constitutive presence of this
sugar in the LPS molecule was suggested to be a major determi-
nant of antimicrobial peptide resistance in Burkholderia sp. (Cox
and Wilkinson, 1991; Vinion-Dubiel and Goldberg, 2003). Ini-
tial attempts in our laboratory to disrupt the genes required for
the synthesis of Ara4N in B. cenocepacia failed, which led to the
hypothesis that this sugar was essential for B. cenocepacia viabil-
ity. Ortega et al. (2007) constructed conditional mutants in this
pathway and showed that both the synthesis of Ara4N and the
transfer of Ara4N to lipid A are essential. Depletion of proteins
from this pathway in conditional mutants resulted in morpholog-
ical changes such as accumulation of membranous material inside
the cell, empty sacculi, and division septa defects, decreased via-
bility as measured by live/dead staining, and increased sensitivity
to detergents (Ortega et al., 2007). The morphological changes
are reminiscent of those observed in mutants of the essential
Lpt pathway, responsible for the translocation of LPS from the
inner membrane to the outer membrane (Sperandeo et al., 2007,
2008). The ﬁrst step in the synthesis of Ara4N is the conversion
of UDP-glucose to UDP-glucuronic acid, a reaction catalyzed by
the protein UDP-glucose dehydrogenase (Ugd; Raetz and Whit-
ﬁeld, 2002). Loutet et al. (2009) showed that the combination of
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two ugd genes, ugdBCAL2946 and ugdBCAM0855, is essential for the
viability of B. cenocepacia, while the most highly expressed gene,
ugdBCAL2946, is required for polymyxin B resistance. As a compo-
nent of the Ara4N synthesis pathway, ugd genes have often been
implicated in antimicrobial peptide resistance in other organisms
(Burtnick and Woods, 1999; Mouslim and Groisman, 2003; Hung
et al., 2007). Although this study links a gene in the Ara4N syn-
thesis pathway with a predicted role in polymyxin B resistance, the
content of Ara4N in the LPS molecule of this mutant has not yet
been determined (Loutet et al., 2009). To date it has not been pos-
sible to assess the precise contribution of Ara4N to antimicrobial
peptide resistance in B. cenocepacia because due to their essen-
tial nature no mutant strain completely lacking Ara4N in the LPS
molecule has been reported in the literature.
A second region of the LPS molecule, the core oligosaccharide,
also contributes to antimicrobial peptide resistance in B. ceno-
cepacia. Progressive truncation of the LPS core oligosaccharide
results in increasing sensitivity of B. cenocepacia to polymyxin
B and increasing binding of polymyxin B to whole cells (Ortega
et al., 2009). A severe LPS core oligosaccharide truncation leads
to the loss of the sugar l-glycero-d-manno-heptose and all sugars
added after these residues. This “deep-rough” truncation typically
causes pleiotropic effects in Gram-negative bacteria (Raetz and
Whitﬁeld, 2002;Valvano et al., 2002). A heptoseless LPS mutant of
B. cenocepacia displayed increased sensitivity to numerous antimi-
crobial agents, and in particular to polymyxin B and to structurally
unrelated antimicrobial peptides such as melittin and human neu-
trophil peptide-1 (Loutet et al., 2006). The mutant strain used in
this study was unable to synthesize l-glycero-d-manno-heptose
and these results were later conﬁrmed in a B. cenocepacia mutant
strain able to synthesize this sugar but unable to transfer it to the
LPS molecule (Ortega et al., 2009).
The other major determinant of resistance described inB. ceno-
cepacia is the alternative sigma factor RpoE (Loutet et al., 2011).
This alternative sigma factor controls the expression of a regulon
of genes that encode proteins required for bacteria to respond to
extracytoplasmic stress (Raina et al., 1995). InB. cenocepacia,RpoE
plays a signiﬁcant role in polymyxin B resistance (but not melittin
resistance; Loutet et al., 2011). It is also required for polymyxin
B resistance at 37˚C but not at 30˚C (Flannagan and Valvano,
2008; Loutet et al., 2011). These results support the notion that
an extremely resistant organism can have resistance determinants
that are required for some compounds but not others and only
under certain conditions.
Three studies have proposed additional minor determinants of
antimicrobial peptide resistance in Burkholderia sp. First, Fehlner-
Gardiner andValvano (2002) demonstrated that in B. vietnamien-
sis, NorM, a member of the multidrug and toxic compound
extrusion family of efﬂux systems (Kuroda and Tsuchiya, 2009),
contributed to polymyxin B resistance, but only in the presence
of exogenously added tetracycline. In the absence of tetracycline,
the efﬂux pump played little part in polymyxin B resistance.
Second, Kooi and Sokol (2009) demonstrated that two secreted
zinc metalloproteases of B. cenocepacia (ZmpA and ZmpB) could
degrade various antimicrobial peptides in vitro but that B. ceno-
cepacia mutant strains lacking either ZmpA, ZmpB, or both did
not exhibit increases in susceptibility to antimicrobial peptides
other than a small increase inmutants lackingZmpB to protamine.
Third, we recently demonstrated that determinants of antimicro-
bial peptide resistance could be identiﬁed in a deep-rough LPS B.
cenocepacia mutant (which lacks one of the major determinants
of antimicrobial peptide resistance). These determinants, which
included a two-component response regulator (BCAL2831), a
periplasmic protease (MucD), and one of two IspH proteins, play
little or no detectable role in a strain with its LPS molecule intact
(Loutet et al., 2011).
Together, these studies provide evidence that extreme resistance
of Burkholderia sp. to antimicrobial peptides is likely multifacto-
rial (Figure 1) and consists of major and minor determinants of
resistance. This led us to propose a two-tier model of antimicro-
bial peptide resistance in B. cenocepacia (Loutet et al., 2011). In the
ﬁrst tier of this model, we hypothesize that the outer membrane
impermeability barrier and poor peptide binding maintained, at
least in part, by unique aspects of the LPS molecule provides the
majority of the resistance seen in this organism in conjunction
with major peptide- or condition-speciﬁc resistance mechanisms
(such as the requirement for RpoE for polymyxin B resistance at
37˚C). In the second tier of the model, we have proposed that vari-
ous other resistance mechanisms exist, each playing a small role in
resistance but as awhole contributing substantially to thehigh total
resistance of the organism. These mechanisms may be difﬁcult to
identify experimentally in the presence of the strong outer mem-
brane impermeability barrier and poor peptide binding mediated
by LPS.
THERE ARE EXCEPTIONS TO EVERY RULE
Of course, there are exceptions to the idea that Burkholderia
bacteria are universally resistant to antimicrobial peptides and
polymyxins (Table 1). In a study using numerous isolates (both
clinical and environmental) of B. vietnamiensis, Jassem et al.
(2011) found that while a large majority of the isolates were
resistant to all of the peptides tested, the growth of one envi-
ronmental isolate (strain FC0656) was inhibited by 37.5μg/ml of
polymyxin B. Thwaite et al. (2009) found that of eight antimi-
crobial peptides tested, seven failed to inhibit the growth of ﬁve
different Burkholderia sp. at up to 256μg/ml of antimicrobial
peptide. However one, magainin II, could inhibit the growth
of many different Burkholderia strains at concentrations rang-
ing from as low as 8 to 256μg/ml. Additionally, the growth
of one strain of B. cepacia was inhibited by a relatively low
concentration (6.6μg/ml) of human β-defensin-3 (García et al.,
2001).
EMERGING OPPORTUNISTS MAY BE EXTREMELY RESISTANT
TO ANTIMICROBIAL PEPTIDES
There is evidence that various emerging opportunistic pathogens
may be extremely resistant to antimicrobial peptides. Coenye et al.
(2002) analyzed a collection of unusual bacteria isolated from CF
patients and misidentiﬁed at hospitals as members of the Bcc.
The authors of this study found various different isolates, most
of which had never or only very rarely been reported as iso-
lated from CF patients. One reason many of these isolates were
misidentiﬁed as members of the Bcc was their ability to grow
on B. cepacia selective agar (BCSA), a media formulated for the
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selection of members of the Bcc. BCSA contains approximately
100μg/ml of polymyxin B, which typically allows for the selec-
tive isolation of Bcc bacteria from other opportunistic pathogens
of CF patients (Henry et al., 1997). Non-Bcc isolates from CF
patients that were able to grow on BCSA included Ralstonia man-
nitolilytica, R. gilardii, Pandoraea sp., Acinetobacter baumannii,
Chromobacterium violaceum,P. huttiensis,Xanthomonas hyacinthi,
and Inquilinus limosus (Coenye et al., 2002). Since this study, a
second report detailed pulmonary infections in 28 CF patients
with Herbaspirillum sp., most of which also grew on BCSA and
were misidentiﬁed as Bcc bacteria (Spilker et al., 2008). These
results show that various organisms, phenotypically similar to
B. cenocepacia and resistant to polymyxin B, have the ability to
infect patients with CF. Finally, treatment of susceptible P. aerug-
inosa (MIC values between 1.6 and 6.1 μg/ml) infections in CF
patients with colistin (polymyxin E) has lead to the isolation of
colistin-resistant P. aeruginosa isolates (MIC values between 100
and 400μg/ml; Johansen et al., 2008).
FUTURE DIRECTIONS OF STUDY
There are multiple experimental lines to continue in the inves-
tigation of antimicrobial peptide and polymyxin resistance in
Burkholderia sp. It is important to determine if Burkholderia bac-
teria make a transcriptional response to antimicrobial peptides.
Since two regulatory systems, RpoE and a two-component system
(BCAL2830/BCAL2831), have been implicated in the resistance
of B. cenocepacia (Loutet et al., 2011) it seems likely that some
transcriptional response occurs upon exposure to antimicrobial
peptides. Genes whose transcription change upon treatment with
antimicrobial peptides, as well as those controlled by RpoE and
BCAL2830/BCAL2831, could prove to be important players in
resistance and provide additional insight into mechanisms of
resistance in these bacteria. The genes regulated by RpoE and
BCAL2830/BCAL2831 have not been identiﬁed, though mucD is
likely regulated by RpoE, since it is in the rpoE operon (Flannagan
and Valvano, 2008), in other organisms rpoE gene expression is
autoregulated (Raina et al., 1995), and preliminary experiments
suggest that this is also the case in B. cenocepacia (El-Halfawy and
Valvano, unpublished).
Understanding the essential nature of Ara4N substitutions of
the LPS molecule in Burkholderia will likely provide signiﬁcant
insight into the unique properties of the outer membrane of these
bacteria that set them apart from other Gram-negative bacteria.
Compounds to disrupt the Ara4N pathway are being developed as
potential therapeutics to administer with antimicrobial peptides
or polymyxins (Kline et al., 2008). Such compounds might be very
powerful anti-Burkholderia agents due to the essential nature of
this pathway.
Since so many pathways have been implicated in the resis-
tance of Burkholderia to antimicrobial peptides and polymyxins,
another avenue to explore that could lead to the development of
an anti-Burkholderia therapeutic is to identify compounds that
synergize with these antibiotics against Burkholderia. We have
recently begun to test this concept with a small library of nat-
urally occurring compounds derived from marine life and have
identiﬁed some potential lead molecules that increase polymyxin
B sensitivity (Loutet and Valvano, unpublished). Other groups
are screening compound libraries to ﬁnd inhibitors of speciﬁc
pathways (De Leon et al., 2006), such as the synthesis of l-glycero-
d-manno-heptose sugars required for the LPS core oligosaccharide
of Gram-negative bacteria (Valvano et al., 2002) and that have
been shown to be required for antimicrobial peptide resistance
and in vivo survival of B. cenocepacia (Loutet et al., 2006). All of
these avenues of future research could potentially lead to a thera-
peutic strategywhere apatientwith aBurkholderia infectionwould
receive a therapeutically applied antimicrobial peptide and a sec-
ond drug that potentiates the activity of the peptide by reducing
bacterial resistance to it.
CONCLUDING REMARKS
Much progress has been made to identify antimicrobial pep-
tide resistance mechanisms in many different Gram-negative and
Gram-positive bacteria (Yeaman and Yount, 2003). These resis-
tance mechanisms include: changes to the cytoplasmic membrane
in both Gram-negative and Gram-positive bacteria (Dorrer and
Teuber, 1977; Peschel et al., 2001), alterations to teichoic acids in
Gram-positive bacteria (Peschel et al., 1999) and LPS in Gram-
negative bacteria (Vaara et al., 1981), efﬂux pumps (Shafer et al.,
1998), proteases (Stumpe et al., 1998; Guina et al., 2000; Caldas
et al., 2002; Belas et al., 2004), exopolysaccharides (Benincasa et al.,
2009; Foschiatti et al., 2009), capsule polysaccharides (Campos
et al., 2004; Spinosa et al., 2007; Llobet et al., 2008), modiﬁcation
of intracellular antimicrobial peptide targets (Vizán et al., 1991),
and the coordination of resistance mechanisms through tran-
scriptional regulation (Gunn and Miller, 1996; Guo et al., 1997;
Humphreys et al., 1999; McPhee et al., 2003; Winﬁeld et al., 2005;
Kraus et al., 2008).
Members of the genus Burkholderia are the best studied
among the highly antimicrobial peptide resistant species of Gram-
negative bacteria, and a series of major and minor resistance deter-
minants have been proposed for these bacteria (Figure 1). Studies
in the Burkholderia could provide a model for the other extremely
resistant Gram-negative bacteria. It is important to understand
resistance in these organisms because many of these bacteria are
opportunistic human pathogens that establish chronic infections.
In this context, using antimicrobial peptides and polymyxins to
treat infections by susceptible bacteria (such as P. aeruginosa infec-
tions in the CF lung) may give rise to subsequent infections by
opportunistic pathogens that are resistant to these compounds.
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